Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels,...
Shares of Biocept Inc. BIOC, 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. Trading volume spiked to 60.9 million shares, compared with the full-day average of about 733,000 shares. the company said in a statement. The...
*****WE KEEP ALERTS SET ON THIS NAME AND BUY ORDER IN PLACE, RUMOR HAS IT THERE IS A MOVE COMING SOON, WITH MASSIVE UPSIDE POTENTIAL******
James mc Carthy from MAxim recently maintained his buy rating and initiated a $3 price target citing.
“Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the...
What I like about BIOC:
1. Higher lows on the daily
2. RSI crossed above the 50
3. MACD still bullish
4. Range to 50ma within reach.
5. Break above 50ma could fill gap to .49
6. MA's in alignment.
7. Showed up on EOD scan - 87% chance of running tomorrow.
The stock is a big % Gainer , it will be in the watchlist of many traders this week and might be going up after its apocalypse
The price now is in a rang between 1.80 and 1.40
If it will break The 1.80 , we have a great probability to go long to the 3.37 ( Last Big top ) forming perhaps a double top for another colapse ( Or not )
If it will break the 1.40 ,...
Biocept has the best-in-breed liquid biopsy testing in the Immuno-Oncology space. Market cap is 70 million, but it's going to be several billion in a few years if they don't get bought out first.
Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of...